FR2549051B1
(fr)
|
1983-06-22 |
1986-05-16 |
Centre Nat Rech Scient |
Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
|
US5262319A
(en)
|
1985-04-19 |
1993-11-16 |
Oncogene Science, Inc. |
Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
|
US5705609A
(en)
|
1988-06-28 |
1998-01-06 |
La Jolla Cancer Research Foundation |
Decorin fragments inhibiting cell regulatory factors
|
US5654270A
(en)
|
1988-06-28 |
1997-08-05 |
La Jolla Cancer Research Foundation |
Use of fibromodulin to prevent or reduce dermal scarring
|
US5583103A
(en)
|
1988-06-28 |
1996-12-10 |
La Jolla Cancer Research Foundation |
Inhibition of transforming growth factor beta activity
|
JP2887325B2
(ja)
|
1988-06-28 |
1999-04-26 |
ラ ホヤ キャンサー リサーチ ファウンデーション |
デコリンによる細胞増殖の抑制
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
WO1991004748A1
(en)
|
1989-09-29 |
1991-04-18 |
La Jolla Cancer Research Foundation |
INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
|
AU639047B2
(en)
|
1989-11-22 |
1993-07-15 |
Genentech Inc. |
Latency associated peptide and uses therefor
|
WO1991010727A1
(en)
|
1990-01-22 |
1991-07-25 |
La Jolla Cancer Research Foundation |
Inhibitors of cell regulatory factors
|
US5554655A
(en)
|
1991-09-30 |
1996-09-10 |
Jess G. Thoene |
Method of treating HIV infection
|
US6008011A
(en)
|
1991-10-31 |
1999-12-28 |
Whitehead Institute For Biomedical Research |
TGF-β type II receptor cDNAs
|
DE69232986T2
(de)
|
1991-10-31 |
2003-12-11 |
Whitehead Biomedical Inst |
TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG
|
ATE233568T1
(de)
|
1991-11-14 |
2003-03-15 |
Jolla Cancer Res Found |
Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung
|
GB9205800D0
(en)
|
1992-03-17 |
1992-04-29 |
British Tech Group |
Treatment of fibrotic disorders
|
US5869462A
(en)
|
1992-09-10 |
1999-02-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
US5821234A
(en)
|
1992-09-10 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
WO1994009812A1
(en)
|
1992-10-26 |
1994-05-11 |
Kirin Brewery Company, Limited |
METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
|
WO1994009815A1
(en)
|
1992-10-29 |
1994-05-11 |
Celtrix Pharmaceuticals, Inc. |
USES OF TGF-β RECEPTOR FRAGMENT AS A THERAPEUTIC AGENT
|
WO1994010187A1
(en)
|
1992-10-30 |
1994-05-11 |
Hsc Research And Development Limited Partnership |
COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)
|
US5830847A
(en)
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
ATE211762T1
(de)
|
1993-04-30 |
2002-01-15 |
Biognostik Ges |
Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
|
EP0737071A1
(en)
|
1993-06-15 |
1996-10-16 |
Il- Yang Pharm. Co., Ltd. |
Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
|
AU8016894A
(en)
|
1993-10-15 |
1995-05-04 |
La Jolla Cancer Research Foundation |
Betaglycan polypeptides having tgf-beta binding activity
|
AU2404695A
(en)
|
1994-05-04 |
1995-11-29 |
Mount Sinai Hospital Corporation |
Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
|
US5772995A
(en)
|
1994-07-18 |
1998-06-30 |
Sidney Kimmel Cancer Center |
Compositions and methods for enhanced tumor cell immunity in vivo
|
CA2156767A1
(en)
|
1994-08-25 |
1996-02-26 |
Kenichi Matsunaga |
Binding agent for growth factor
|
JPH08119984A
(ja)
|
1994-08-31 |
1996-05-14 |
Nkk Corp |
ストレプトミセス属放線菌及びこの菌由来のTGF−β 阻害剤
|
US5824655A
(en)
|
1995-02-15 |
1998-10-20 |
The University Of Utah |
Anti-transforming growth factor-β gene therapy
|
US5714519A
(en)
|
1995-06-07 |
1998-02-03 |
Ergo Science Incorporated |
Method for regulating glucose metabolism
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
JP2000510112A
(ja)
|
1996-04-30 |
2000-08-08 |
ジェンザイム コーポレーション |
TGF―β拮抗物質としてのプロラクチンの使用方法
|
JPH1067674A
(ja)
|
1996-06-19 |
1998-03-10 |
Advanced Sukin Res Kenkyusho:Kk |
細胞外マトリツクスの異常蓄積抑制剤
|
EP0956036B1
(en)
|
1996-10-25 |
2005-12-14 |
Ethicon, Inc. |
Anti-fibrotic agent assay
|
NZ500284A
(en)
|
1997-04-18 |
2001-09-28 |
Biogen Inc |
Type II TGF-beta receptor fusion proteins
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
US6468522B1
(en)
|
1999-07-22 |
2002-10-22 |
University Of Medicine And Dentistry Of New Jersey |
Controlled release of thioamide moiety-containing therapeutic agents
|
US6521266B1
(en)
|
1999-09-23 |
2003-02-18 |
Morris A. Mann |
Composition for growth hormone production and release, appetite suppression, and methods related thereto
|
ES2237671T3
(es)
|
2001-02-02 |
2005-08-01 |
Smithkline Beecham Corporation |
Derivados de pirazol contra la sobreexpresion de tgf.
|
GB0102665D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
GB0102668D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
GB0102673D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
GB0102672D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
EP1363904A1
(en)
|
2001-02-02 |
2003-11-26 |
Glaxo Group Limited |
Pyrazoles as tgf inhibitors
|
EA007782B1
(ru)
|
2001-05-24 |
2007-02-27 |
Эли Лилли Энд Компани |
Новые производные пиррола в качестве фармацевтических средств
|
AR039241A1
(es)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
EP1506191A1
(en)
|
2002-05-15 |
2005-02-16 |
Smithkline Beecham Corporation |
Benzoxazine and benzoxazinone substituted triazoles
|
WO2003097615A1
(en)
|
2002-05-17 |
2003-11-27 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
|
EP1575506A4
(en)
|
2002-07-25 |
2008-04-23 |
Scios Inc |
METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS
|
GB0217786D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Compounds
|
UA80296C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
UA80295C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
EP1549316A4
(en)
|
2002-09-10 |
2008-04-09 |
Scios Inc |
HAMMER OF TFGbeta
|
AU2003268156A1
(en)
|
2002-09-17 |
2004-04-08 |
Eli Lilly And Company |
Novel pyrazolopyridine derivatves as pharmaceutical agents
|
AU2003268155A1
(en)
|
2002-09-19 |
2004-04-08 |
Eli Lilly And Company |
Methods of inhibiting tgf beta with substituted pyrazoles
|
AU2003291149A1
(en)
|
2002-11-22 |
2004-06-18 |
Scios, Inc. |
USE OF TFG-Beta INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
|
CA2506978A1
(en)
|
2002-11-22 |
2004-06-10 |
Scios, Inc. |
Method for counteracting a pathologic change in the b-adrenergic pathway
|
UA80571C2
(en)
|
2002-11-22 |
2007-10-10 |
Lilly Co Eli |
Quinolinyl-pyrrolopyrazoles
|
US20060079680A1
(en)
|
2002-11-22 |
2006-04-13 |
Eli Lilly And Company Patent Division |
Pyrazoloazepine compounds as pharmaceutical agents
|
AU2003290734A1
(en)
|
2002-11-27 |
2004-06-23 |
Eli Lilly And Company |
Novel compounds as pharmaceutical agents
|
AU2003297460A1
(en)
|
2002-12-19 |
2004-07-14 |
Scios, Inc. |
TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
|
CL2004000234A1
(es)
|
2003-02-12 |
2005-04-15 |
Biogen Idec Inc |
Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
|
WO2004087056A2
(en)
|
2003-03-28 |
2004-10-14 |
Scios Inc. |
BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
|
WO2005010049A2
(en)
|
2003-07-09 |
2005-02-03 |
Eli Lilly And Company |
Tgf-beta1 ligands
|
WO2005032481A2
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
Quinazoline derivatives as medicaments
|
EP1708712A1
(en)
|
2003-12-24 |
2006-10-11 |
Scios, Inc. |
Treatment of malignant gliomas with tgf-beta inhibitors
|
US7368445B2
(en)
|
2004-03-01 |
2008-05-06 |
Eli Lilly And Company |
Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms
|
RU2386638C2
(ru)
|
2004-03-31 |
2010-04-20 |
Дженентек, Инк. |
Гуманизированные анти-тфр-бета-антитела
|
DE102004019253A1
(de)
|
2004-04-16 |
2005-11-10 |
Codewrights Gmbh |
Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
|
JP2008511630A
(ja)
|
2004-08-31 |
2008-04-17 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
TGF−βインヒビターとしてのピリミジニルピラゾール
|
CA2578630A1
(en)
|
2004-08-31 |
2006-03-09 |
Wen-Cherng Lee |
Pyrimidinylimidazoles as tgf-beta inhibitors
|
WO2006052568A2
(en)
|
2004-11-10 |
2006-05-18 |
Eli Lilly And Company |
Tgf-beta inhibitors
|
CN101163502A
(zh)
|
2005-02-08 |
2008-04-16 |
根茨美公司 |
针对TGFβ的抗体
|
EP2535044B1
(en)
|
2006-01-27 |
2019-12-18 |
The Regents of The University of California |
Enterically coated cysteamine bitartrate and cystamine
|
WO2008070117A1
(en)
*
|
2006-12-04 |
2008-06-12 |
Promedior, Inc. |
Conjoint therapy for treating fibrotic diseases
|
DK2214480T3
(da)
|
2007-11-30 |
2013-07-08 |
Univ California |
Fremgangsmåder til behandling af nonalkoholisk steatohepatitis (NASH) ved anvendelse af cysteaminprodukter
|